MedTrace Logo

Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)

NCT03391973 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-07-02

Study results available
· View outcomes & findings →

Summary

Abbreviated Title: Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis carcinoma of unknown primary site Trial Type: Single arm phase 2 Type of control: Not applicable Route of administration: Intravenous Trial Blinding: Not applicable Treatment Groups: 1) Pembrolizumab 200 mg IV every 3 weeks for up to 24 months. Total Number of trial subjects:25 Estimated enrollment period: 24 months Estimated duration of trial: 48 months Duration of Participation: 24 months

Conditions

  • Carcinoma of Unknown Primary

Interventions

DRUG

Pembrolizumab Injection

Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.

Sponsors & Collaborators

  • Tom Baker Cancer Centre

    collaborator OTHER

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Jose Monzon, MD · Arthur J.E. Child Comprehensive Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-24
Primary Completion
2023-06-16
Completion
2026-02-12
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03391973 on ClinicalTrials.gov